{
  "label": "q_cs03_q14_paraphrase",
  "artifact_type": "question",
  "artifact_id": "sha256:8f857f082baaed501d39859b8fbb6f4f955da3f8a792652c13ca7b7ca53c16bd",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:cab0ed69f1fa476255e68bf8c3e4cc9b8de1271b593421292819215fb07dd0fd",
    "sha256:044266001cadd958fbee4c3c26f47dd870c06eeeaffdc51d0bcca59d174fce62",
    "sha256:ace01eb11bd178d41631a87820db3d0b38695724566df0e4cf754bd0d2a63a06",
    "sha256:354f39bfec1a0c86100323c7a427f76857c2be890762578cd0f4f46cabe47110"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:44.859949",
  "content": "{\n  \"question_id\": \"cs03_q14_paraphrase\",\n  \"scope_id\": \"clinical_signal_03\",\n  \"checkpoint_after\": 25,\n  \"question_type\": \"paraphrase\",\n  \"prompt\": \"Why is there a difference in liver enzyme levels between patient subgroups?\",\n  \"ground_truth\": {\n    \"canonical_answer\": \"A drug-drug interaction between LNS-4821 and concomitant statin therapy via CYP3A4 inhibition causes hepatotoxicity in the statin subgroup. The signal appears across all sites, not just Site 07, ruling out the equipment calibration hypothesis.\",\n    \"required_evidence_refs\": [\n      \"clinical_signal_03_ep_010\",\n      \"clinical_signal_03_ep_018\",\n      \"clinical_signal_03_ep_023\",\n      \"clinical_signal_03_ep_015\"\n    ],\n    \"key_facts\": [\n      \"ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases\",\n      \"multi-site signal distribution rules out site-specific confounders as causal explanation\",\n      \"the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity\",\n      \"Site 07 lab equipment issue is not the cause of ALT elevations\"\n    ]\n  }\n}",
  "metadata": {
    "question_id": "cs03_q14_paraphrase",
    "question_type": "paraphrase",
    "checkpoint_after": 25,
    "scope_id": "clinical_signal_03",
    "layer_name": "questions",
    "layer_level": 3,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "8408d509ce2f758b019c46f1778ff2480df851f770129b537e5477ca6a33d8bb",
      "components": {
        "transform": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
        "inputs": "c2449f1586e9e4bc"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
      "components": {
        "transform_id": "3176c030aaa3a69e",
        "source": "929fe273ac2dab06",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}